- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00974012
Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions
September 9, 2009 updated by: Teva Pharmaceuticals USA
A Relative Bioavailability Study of 500 mg Divalproex Sodium Extended Release Tablets Under Non-Fasting Conditions
This study was designed to compare the relative bioavailability (rate and extent of absorption) of Divalproex Sodium ER Tablets 500 mg with that of Depakote® ER Tablets 500 mg following a single, oral dose (1 x 500 mg extended release tablet) administered to healthy, adult subjects under non-fasting conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
East Grand Forks, Minnesota, United States, 56721
- PRACS Institute, Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria
- Subjects who have completed the screening process within 28 days prior to Period 1 dosing
- Subjects who are healthy adult men and women 18 years of age or older at the time of dosing.
- Subjects who have a body mass index (BMI) between 19-30 kg/m2, inclusive, and weigh at least 110 lbs.
- Subjects who are healthy as documented by the medical history, physical examination (including bur may not be limited to and evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems), vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and by general observations. Any abnormalities/deviations from the normal range that might be considered clinically relevant by the study physician and investigator will be evaluated for individual cases, documented in study files and agreed upon by both the study physician and investigator prior to enrolling the subject in this study and for continued enrollment.
- Female subjects of postmenopausal (no menses) status for at least 1 year and has a serum FSH level greater than or equal to 30 mIU/mL or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).
Exclusion Criteria
- Subjects who report receiving any investigational drug within 30 days prior to Period 1 dosing.
- Subjects who report any presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined by the clinical investigator(s).
- Subjects whose clinical laboratory test values outside the accepted reference range and when confirmed on re-examination is deemed to be clinically significant.
- Subjects who demonstrate a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
- Subjects who report a history or allergic response(s) to divalproex or related drugs.
- Subjects who report the use of any systemic prescription medication in the 14 days prior to Period 1 dosing.
- Subjects who report the use of any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period 1 dosing.
- Subjects who report a history of clinically significant allergies including drug allergies.
- Subjects who report a clinically significant illness during the 4 weeks prior to Period 1 dosing (as determined by the clinical investigators).
- Subjects who report a history of drug or alcohol addiction or abuse within the past year.
- Subjects who demonstrate a positive drug abuse screen for this study prior to Period 1 administration.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Divalproex Sodium
500 mg Extended Release Tablet
|
500 mg ER Tablet
|
Active Comparator: Depakote®
500 mg Extended Release Tablet
|
500 mg ER Tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax - Maximum Observed Concentration
Time Frame: Blood samples collected over 72 hour period
|
Blood samples collected over 72 hour period
|
AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)
Time Frame: Blood samples collected over 72 hour period
|
Blood samples collected over 72 hour period
|
AUC0-t - Area under the concentration-time curve from time zero to time of last quantifiable concentration (per participant)
Time Frame: Blood samples collected over 72 hour period
|
Blood samples collected over 72 hour period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
October 1, 2006
Study Completion (Actual)
October 1, 2006
Study Registration Dates
First Submitted
September 9, 2009
First Submitted That Met QC Criteria
September 9, 2009
First Posted (Estimate)
September 10, 2009
Study Record Updates
Last Update Posted (Estimate)
September 10, 2009
Last Update Submitted That Met QC Criteria
September 9, 2009
Last Verified
September 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R06-0442
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Divalproex Sodium
-
Vince & Associates Clinical Research, Inc.Food and Drug Administration (FDA)Unknown
-
National Cancer Institute (NCI)CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited States
-
Bo-Hyun YoonWithdrawnBipolar DepressionKorea, Republic of
-
Beth Israel Deaconess Medical CenterNational Cancer Institute (NCI); Dana-Farber Cancer Institute; National Institutes...Recruiting
-
National Institute on Alcohol Abuse and Alcoholism...University of PittsburghCompleted
-
AbbottTerminated
-
Boston Children's HospitalUniversity of LouisvilleWithdrawn
-
New York State Psychiatric InstituteCompletedIrritable AggressionUnited States
-
AbbottCompleted